Portal del Investigador
GENOMICALLY STABLE GASTRIC CANCER: YAP1 AS A PREDICTOR OF STANDARD THERAPY RESPONSE AND NOVEL TARGET FOR PRECISION MEDICINE.
Más información
| Fecha de publicación: | 2022 |
| Objetivos: | To evaluate the potential of YAP1 for predicting response to standard therapy and propose Yap1 inhibition as a targeted therapy for precision medicine in genomically stable gastric cancer |
| Instrumento: | Fondecyt Regular |
| Año de Inicio/Término: | 2022-2025 |
| Financiamiento/Sponsor: | CONICYT |
| Rol del Usuario: | INVESTIGADOR(A) RESPONSABLE |
| DOI: |
1221253 |